The award was presented to the St. Baldrick’s Foundation-Stand Up 2 Cancer Pediatric Cancer Dream Team, co-led by CHOP, at the annual AACR conference.

Award recognizes a researcher who has translated a proof-of-concept study to widespread clinical practice.

Established in 2015, the Evan Lindberg Neuroblastoma Research Scholars Program supports exceptional early-career scientists at CHOP who are dedicated to finding a cure for neuroblastoma.

Supplement proved effective at preventing the formation of amyloid proteins, which may lead to treatments for certain forms of dementia.

Large study provides head impact sensor analysis across four sports and both genders, a first for basketball and field hockey.

CHOP researchers will receive funds to discover a new drug that targets MYCN, a transcription factor involved in some pediatric cancers.

The findings identify possible targets for future therapies for ribosomopathies, childhood disorders that lead to bone marrow failure (BMF).

CHOP researchers have identified RNA editing events that influence gene expression and phenotype, showing that a single nucleotide change can have large downstream effects.

CHOP expert leading the effort to develop a chatbot to screen children for suicide risk in a more efficient and scalable manner.

Using deep immune profiling, CHOP researchers have found children with MIS-C are extremely immune activated, more like adults with severe COVID-19.